ZQ Capital Management

Cavendish is delighted to announce our involvement in advising ZQ Capital Management and SkyGem Acquisition on a novel refinancing package supporting Allergy Therapeutics PLC, involving the provision of debt, equity, and a mandatory offer under the Takeover Code.

Seamus Fricker, Public M&A at Cavendish, commented:

 “ZQ Capital Management are a long-standing advisory client of the firm and we are proud of our part in putting this creative solution together so that ZQ have been able to provide support for Allergy Therapeutics. This funding assist with the continuation of the pivotal Phase III G306 trial and other key clinical trials including the Phase I study for Peanut allergy.”